# The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Study · id `cardio:ct-nct06606821` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06606821](<https://clinicaltrials.gov/study/NCT06606821>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06606821

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 124 participants.

## Technical summary

Registry record NCT06606821. Randomized; triple masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2027-03-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 124 participants (planned count; ClinicalTrials.gov record NCT06606821, source copy `cardio:ctgov-nct06606821-2025-05-22`, retrieved 2026-10-26)
- Started: 2024-10-01 (actual) (ClinicalTrials.gov record NCT06606821, source copy `cardio:ctgov-nct06606821-2025-05-22`, retrieved 2026-10-26)
- Primary completion: 2027-03-20 (anticipated) (ClinicalTrials.gov record NCT06606821, source copy `cardio:ctgov-nct06606821-2025-05-22`, retrieved 2026-10-26)
- Completion: 2028-08-01 (anticipated) (ClinicalTrials.gov record NCT06606821, source copy `cardio:ctgov-nct06606821-2025-05-22`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06606821, source copy `cardio:ctgov-nct06606821-2025-05-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06606821-2025-05-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
- Acronym: IDEAL-COR
- Condition: Coronary Artery Disease
- Condition: Coronary Microvascular Dysfunction
- Condition: Overweight or Obesity
- Condition: Stable Angina Pectoris
- Condition: Chronic Coronary Artery Disease
- Condition: Atherosclerosis Cardiovascular Disease
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Placebo
- Lead sponsor: Tina Vilsbøll
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: 5844a4e3856090d4c14c57052ef5c04de480abe5a6f14953f9960070d44bd026
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
